Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Dasatinib × Other solid neoplasm × Clear all

Phase

Phase 1 4 Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 12 Lymphoid 7 Breast 6 Myeloid 4 Sarcoma 3 Genitourinary 3 CNS 3 Thoracic 2 Other solid neoplasm 1 Gynecologic 1 Gastrointestinal 1 Dermatologic 1

Conditions

Prostate Cancer Recurrent 1

Interventions

pembrolizumab 37 Injections 33 toripalimab 20 Bevacizumab 16 Nivolumab 15 Cisplatin 15 Pemetrexed 14 Paclitaxel 14 Cyclophosphamide 14 Carboplatin 14 fludarabine 9 Irinotecan 9 Ipilimumab 9 tislelizumab 8 Leucovorin 8 Gemcitabine 8 Fluorouracil 8 Docetaxel 8 atezolizumab 7 spartalizumab 6 Oxaliplatin 6 Albumin-Bound Paclitaxel 5 trifluridine tipiracil drug combination 4 sintilimab 4 palbociclib 4 lenvatinib 4 Radiosurgery 4 Interleukin-2 4 Fulvestrant 4 Capecitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05036226 2025-10-06

COAST

Medical University of South Carolina

Phase 1/2 Recruiting

GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡